Andrei Thomas-Tikhonenko

List of Publications by Year
in descending order

82 papers	8,454 citations	94433 37 h-index	64796 79 g-index
94 all docs	94 docs citations	94 times ranked	15058 citing authors

#	Article	IF	Citations
1	Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 2008, 40, 43-50.	21.4	1,203
2	Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nature Genetics, 2006, 38, 1060-1065.	21.4	1,000
3	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	9.4	997
4	Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation, 2007, 117, 326-336.	8.2	983
5	Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3384-3389.	7.1	355
6	ER stressâ€“mediated autophagy promotes Myc-dependent transformation and tumor growth. Journal of Clinical Investigation, 2012, 122, 4621-4634.	8.2	336
7	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-Î² Pathway in Neuroblastoma. Molecular Cell, 2010, 40, 762-773.	9.7	279
8	The Mycâ€“miR-17â^¼92 Axis Blunts TGFÎ² Signaling and Production of Multiple TGFÎ²-Dependent Antiangiogenic Factors. Cancer Research, 2010, 70, 8233-8246.	0.9	248
9	Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity. Molecular and Cellular Biology, 2004, 24, 8541-8555.	2.3	227
10	Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis. Molecular and Cellular Biology, 2006, 26, 2373-2386.	2.3	210
11	CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances, 2019, 3, 3539-3549.	5.2	145
12	p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers. Cancer Research, 2011, 71, 7490-7501.	0.9	144
13	B cellâ€“specific loss of histone 3 lysine 9 methylation in the VH locus depends on Pax5. Nature Immunology, 2004, 5, 853-861.	14.5	113
14	Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13968-13973.	7.1	111
15	Oncogenic BRAF regulates Î²-Trcp expression and NF-ÎºB activity in human melanoma cells. Oncogene, 2007, 26, 1954-1958.	5.9	94
16	Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. Journal of the National Cancer Institute, 2009, 101, 663-677.	6.3	87
17	CD19 is a major B cell receptorâ€“independent activator of MYC-driven B-lymphomagenesis. Journal of Clinical Investigation, 2012, 122, 2257-2266.	8.2	87
18	Viral Myc Oncoproteins in Infected Fibroblasts Down-modulate Thrombospondin-1, a Possible Tumor Suppressor Gene. Journal of Biological Chemistry, 1996, 271, 30741-30747.	3.4	80

#	Article	IF	Citations
19	Role of GLI2 Transcription Factor in Growth and Tumorigenicity of Prostate Cells. Cancer Research, 2007, 67, 10642-10646.	0.9	78
20	Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. American Journal of Hematology, 2017, 92, E11-E13.	4.1	78
21	Activation of the Myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Research, 2000, 28, 2268-2275.	14.5	76
22	Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene, 2011, 30, 2587-2594.	5.9	73
23	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood, 2013, 122, 4220-4229.	1.4	70
24	Myc-Transformed Epithelial Cells Down-Regulate Clusterin, Which Inhibits Their Growth in Vitro and Carcinogenesis in Vivo. Cancer Research, 2004, 64, 3126-3136.	0.9	68
25	Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis. Journal of Immunology, 2001, 166, 5878-5881.	0.8	65
26	Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia, 2020, 34, 1202-1207.	7.2	61
27	Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood, 2003, 101, 1950-1955.	1.4	58
28	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in BÂcells. Nature, 2020, 588, 491-497.	27.8	57
29	CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum. Molecular and Cellular Biology, 2018, 38, .	2.3	55
30	c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biology and Therapy, 2008, 7, 1758-1764.	3.4	54
31	Shielding the messenger (RNA): microRNA-based anticancer therapies. , 2011, 131, 18-32.		52
32	A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene, 2002, 21, 1922-1927.	5.9	51
33	Targeting Î²-Transducin Repeatâ€“Containing Protein E3 Ubiquitin Ligase Augments the Effects of Antitumor Drugs on Breast Cancer Cells. Cancer Research, 2005, 65, 1904-1908.	0.9	51
34	MYC and the Art of MicroRNA Maintenance. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014175-a014175.	6.2	51
35	Functional Validation of Genes Implicated in Lymphomagenesis: Anin VivoSelection Assay Using a Myc-Induced B-Cell Tumor. Annals of the New York Academy of Sciences, 2005, 1059, 145-159.	3.8	45
36	Targeting of TGFÂ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. Rna, 2013, 19, 177-190.	3.5	45

#	Article	IF	Citations
37	Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. American Journal of Hematology, 2018, 93, E352-E355.	4.1	44
38	Regulation of CLU Gene Expression by Oncogenes and Epigenetic Factors. Advances in Cancer Research, 2009, 105, 115-132.	5.0	40
39	Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Research, 2018, 46, 11357-11369.	14.5	39
40	miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis. Annals of Hematology, 2016, 95, 881-891.	1.8	37
41	B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. Journal of Clinical Investigation, 2007, 117, 2602-2610.	8.2	37
42	Infection and cancer: the common vein. Cytokine and Growth Factor Reviews, 2003, 14, 67-77.	7.2	31
43	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Blood Cancer Discovery, 2022, 3, 103-115.	5.0	31
44	Inactivation of Myc in Murine Two-Hit B lymphomas Causes Dormancy with Elevated Levels of Interleukin 10 Receptor and CD20: Implications for Adjuvant Therapies. Cancer Research, 2005, 65, 5454-5461.	0.9	29
45	p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood, 2007, 109, 4936-4943.	1.4	29
46	Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biology and Therapy, 2007, 6, 1433-1437.	3.4	24
47	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia, 2019, 33, 2429-2441.	7.2	24
48	Escape From ALL-CARTaz. Cancer Journal (Sudbury, Mass), 2019, 25, 217-222.	2.0	20
49	Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts. Genome Biology, 2021, 22, 190.	8.8	20
50	gag as well as myc sequences contribute to the transforming phenotype of the avian retrovirus FH3. Journal of Virology, 1992, 66, 946-955.	3.4	20
51	Inhibition of the Single Downstream Target BAG1 Activates the Latent Apoptotic Potential of MYC. Molecular and Cellular Biology, 2011, 31, 5037-5045.	2.3	18
52	An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biology and Therapy, 2003, 2, 687-93.	3.4	17
53	The long reach of noncoding RNAs. Nature Genetics, 2011, 43, 616-617.	21.4	16
54	Masking Epistasis Between MYC and TGF-Î² Pathways in Antiangiogenesis-Mediated Colon Cancer Suppression. Journal of the National Cancer Institute, 2014, 106, dju043.	6.3	15

#	Article	IF	Citations
55	RNA-binding proteins of COSMIC importance in cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	15
56	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nature Communications, 2022, 13, 2228.	12.8	14
57	MOCCASIN: a method for correcting for known and unknown confounders in RNA splicing analysis. Nature Communications, 2021, 12, 3353.	12.8	12
58	Tilting MYC toward cancer cell death. Trends in Cancer, 2021, 7, 982-994.	7.4	12
59	B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages. Experimental Cell Research, 2007, 313, 331-340.	2.6	11
60	Identifying common transcriptome signatures of cancer by interpreting deep learning models. Genome Biology, 2022, 23, 117.	8.8	11
61	MYC Hyperactivates Wnt Signaling in APC/CTNNB1-Mutated Colorectal Cancer Cells through miR-92aâ€“Dependent Repression of DKK3. Molecular Cancer Research, 2021, 19, 2003-2014.	3.4	9
62	Intratumoral delivery of an interferon gamma retrovirus-producing cells inhibits growth of a murine melanoma by a non-immune mechanism. Cancer Letters, 2001, 173, 145-154.	7.2	8
63	Epigenetic Histone Modifications Do Not Control Igĺº Locus Contraction and Intranuclear Localization in Cells with Dual B Cell-Macrophage Potential. Journal of Immunology, 2006, 177, 6165-6171.	0.8	7
64	PAX5 and B-cell neoplasms: transformation through presentation. Future Oncology, 2008, 4, 5-9.	2.4	7
65	Avian endogenous provirus (ev-3) env gene sequencing: Implication for pathogenic retrovirus origination. Virus Genes, 1990, 3, 251-258.	1.6	6
66	Infection & Neoplastic Growth 101. Cancer Treatment and Research, 2006, , 167-197.	0.5	6
67	Distribution of mouse mammary tumor virus-related sequences does not correlate with the taxonomic position of their hosts. Virus Genes, 1990, 4, 85-92.	1.6	4
68	Long terminal repeats of dwarf hamster endogenous retrovirus are highly diverged and do not maintain efficient transcription. Virology, 1991, 181, 367-370.	2.4	4
69	Kit-activating mutations in AML: Lessons from PU.1-induced murine erythroleukemia. Cancer Biology and Therapy, 2006, 5, 579-581.	3.4	4
70	Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/Î²-Catenin Signaling through Enhanced Smad4â€“LEF1 Binding. Molecular Cancer Research, 2021, 19, 823-833.	3.4	4
71	Molecular cloning and primary structure analysis of the mouse mammary tumor virus-related element from dwarf hamster genome. Virus Genes, 1990, 3, 259-261.	1.6	3
72	Whence Thrombospondin?. Cancer Biology and Therapy, 2004, 3, 406-407.	3.4	3

#	Article	IF	Citations
73	Regulation of CD19 Exon 2 Inclusion in B-Lymphoid Cells By Splicing Factors and Epigenetic Marks. Blood, 2015, 126, 2425-2425.	1.4	3
74	The Importance of CD19 Exon 2 for Surface Localization: Closing the Ig-like Loop. Blood, 2015, 126, 3433-3433.	1.4	3
75	Exons of Leukemia Suppressor Genes: Creative Assembly Required. Trends in Cancer, 2018, 4, 796-798.	7.4	2
76	Pipeline for Discovering Neoepitopes Generated By Alternative Splicing in B-ALL. Blood, 2019, 134, 1342-1342.	1.4	2
77	Aiding and ABTâ€™ing treatment for glioblastoma. Cancer Biology and Therapy, 2007, 6, 802-804.	3.4	1
78	Myc and Control of Tumor Neovascularization. , 2010, , 167-187.		1
79	Poisoning the Messengers: Could Tumor Endothelial Cells Acquire Drug Resistance. Cancer Biology and Therapy, 2002, 1, 266-267.	3.4	0
80	Abstract B33: Transient upregulation of Myc with GSK3-Î² inhibitors in B-cell lymphomas enhances p53-independent apoptotic responses to chemotherapy. , 2015, , .		0
81	The Impact of Immunotherapy on Tumor Evolution. Blood, 2018, 132, SCI-18-SCI-18.	1.4	0
82	Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation. Blood, 2021, 138, 868-868.	1.4	0